Brian Stuglik, R.Ph.
Mr. Stuglik was appointed as a director and as a member of the Commercial Committee of
Puma Biotechnology on July 5, 2020. He served as Chief Executive Officer of Verastem, Inc.
from July 2019 through July 2023 and has served as a member of its Board of Directors since
September 2017. He has also served as a member of the Board of Directors of Oncopeptides
AB since May 2018.
Mr. Stuglik founded Proventus Health Solutions in January 2016 and has over three decades of
experience in U.S. and international pharmaceutical development, product strategy, and
commercialization. Prior to founding Proventus Health Solutions, Mr. Stuglik served as the Vice
President and Chief Marketing Officer for the oncology division of Eli Lilly and Company, from
2009 to December 2015.
Mr. Stuglik received a Bachelor of Science in Pharmacy from Purdue University and holds
memberships in the American Society of Clinical Oncology, the American Association of Cancer
Research, and the International Association for the Study of Lung Cancer. Mr. Stuglik was
selected as a director because of his significant experience and background in the life sciences
industry and, in particular, commercialization of pharmaceutical therapies.
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024